Market Size of Advanced Therapy Medicinal Products (ATMP) CDMO Industry
| Study Period | 2021 - 2029 |
| Market Size (2024) | USD 6.04 Billion |
| Market Size (2029) | USD 17.98 Billion |
| CAGR (2024 - 2029) | 24.40 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Advanced Therapy Medicinal Products (ATMP) CDMO Market Analysis
The Advanced Therapy Medicinal Products CDMO Market size is estimated at USD 6.04 billion in 2024, and is expected to reach USD 17.98 billion by 2029, growing at a CAGR of 24.40% during the forecast period (2024-2029).
Major factors propelling the growth of the advanced therapy medicinal products (ATMP) market include increasing clinical trials in the ATMP space and growing demand for outsourcing in the pharmaceutical industry.
Advanced therapeutic medicinal products (AMTPs) give patients revolutionary therapy modalities for previously thought to be incurable conditions. While gene therapies like Zolgensma have demonstrated long-term efficacy in treating infants with spinal muscular atrophy (SMA), CAR-T cell therapies have shown significant results in treating some blood malignancies. For instance, in May 2023, REPROCELL expanded its offerings to include contract development and manufacturing organization (CDMO) services, focusing on the production of advanced therapy medicinal products (ATMPs) derived from mesenchymal stem cells (MSCs). This strategic expansion results from a partnership with Histocell, allowing REPROCELL to bolster its capabilities in the field of advanced therapeutic products.
Similarly, in September 2023, Charles River Laboratories International Inc. launched its lentiviral vector (LVV) manufacturing platform, Lentivation. The platform can reduce LVV manufacturing timelines for gene and gene-modified cell therapies by up to 60%, translating to fewer than seven months compared to traditional manufacturing workflows. With such emerging advancements, there is likely to be a growing demand for CDMOs, which is believed to propel market growth in the coming years.
The astonishing speed with which it has responded to difficulties demonstrates the industry's resilience and global nature. Most people in the world have profited from the services these businesses offer. For instance, according to the Contract Pharma Journal data published in February 2022, the biopharmaceutical CDMO companies have seen an average 29% rise in revenue from 2021 to 2022 for advanced therapies such as cell and gene therapy.
However, the high cost associated with CDMO and stringent regulatory policies are some of the factors hindering market growth.
Advanced Therapy Medicinal Products (ATMP) CDMO Industry Segmentation
As per the scope of the report, advanced therapy medicinal products (ATMP) are human-use medicines based on genes, tissues, or cells. The advanced therapy medicinal products (ATMP) CDMO market is segmented by product, phase, indication, and geography. The product segment is divided into gene therapy, cell therapy, tissue engineering, and other products. The phase segment is further segmented into phase I, phase II, phase III, and phase IV. The indication segment is bifurcated into oncology, cardiology, neurology, infectious diseases, and other indications. The geography is further divided into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value in USD for the above segments.
| By Product | |
| Gene Therapy | |
| Cell Therapy | |
| Tissue Engineering | |
| Other Products |
| By Phase | |
| Phase I | |
| Phase II | |
| Phase III | |
| Phase IV |
| By Indication | |
| Oncology | |
| Cardiology | |
| Neurology | |
| Infectious Disease | |
| Other Indications |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Advanced Therapy Medicinal Products (ATMP) CDMO Market Size Summary
The Advanced Therapy Medicinal Products (ATMP) CDMO market is poised for substantial growth, driven by increasing clinical trials and a rising demand for outsourcing within the pharmaceutical sector. ATMPs, which include innovative therapies like gene and CAR-T cell therapies, are transforming treatment options for previously incurable conditions. The market is witnessing strategic expansions and technological advancements, such as REPROCELL's partnership with Histocell and Charles River Laboratories' launch of the Lentivation platform, which are expected to enhance manufacturing capabilities and reduce production timelines. These developments underscore the growing reliance on Contract Development and Manufacturing Organizations (CDMOs) to meet the burgeoning demand for advanced therapeutic solutions.
The market's expansion is further supported by the establishment of new facilities and collaborations among key industry players. Companies like eXmoor Pharma and Avirmax CMC Inc. are enhancing their capabilities to support gene therapy production, while RoslinCT and Lykan Bioscience have unified their operations to strengthen their market position. North America, with its robust pharmaceutical industry and significant CDMO presence, is a major contributor to market growth. The region's focus on gene therapy and the strategic outsourcing of production to CDMOs are facilitating the development of advanced treatments for rare and genetic diseases. Despite challenges such as high costs and regulatory hurdles, the market is expected to grow significantly, driven by new product launches and increased CDMO activities.
Advanced Therapy Medicinal Products (ATMP) CDMO Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Clinical Trials in ATMP
-
1.2.2 Growing Demand for Outsourcing in Pharmaceutical Industry
-
-
1.3 Market Restraints
-
1.3.1 High Cost of CDMO
-
1.3.2 Stringent Regulatory Policies
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Value in USD)
-
2.1 By Product
-
2.1.1 Gene Therapy
-
2.1.2 Cell Therapy
-
2.1.3 Tissue Engineering
-
2.1.4 Other Products
-
-
2.2 By Phase
-
2.2.1 Phase I
-
2.2.2 Phase II
-
2.2.3 Phase III
-
2.2.4 Phase IV
-
-
2.3 By Indication
-
2.3.1 Oncology
-
2.3.2 Cardiology
-
2.3.3 Neurology
-
2.3.4 Infectious Disease
-
2.3.5 Other Indications
-
-
2.4 Geography
-
2.4.1 North America
-
2.4.1.1 United States
-
2.4.1.2 Canada
-
2.4.1.3 Mexico
-
-
2.4.2 Europe
-
2.4.2.1 Germany
-
2.4.2.2 United Kingdom
-
2.4.2.3 France
-
2.4.2.4 Italy
-
2.4.2.5 Spain
-
2.4.2.6 Rest of Europe
-
-
2.4.3 Asia-Pacific
-
2.4.3.1 China
-
2.4.3.2 Japan
-
2.4.3.3 India
-
2.4.3.4 Australia
-
2.4.3.5 South Korea
-
2.4.3.6 Rest of Asia-Pacific
-
-
2.4.4 Middle East and Africa
-
2.4.4.1 GCC
-
2.4.4.2 South Africa
-
2.4.4.3 Rest of Middle East and Africa
-
-
2.4.5 South America
-
2.4.5.1 Brazil
-
2.4.5.2 Argentina
-
2.4.5.3 Rest of South America
-
-
-
Advanced Therapy Medicinal Products (ATMP) CDMO Market Size FAQs
How big is the Advanced Therapy Medicinal Products CDMO Market?
The Advanced Therapy Medicinal Products CDMO Market size is expected to reach USD 6.04 billion in 2024 and grow at a CAGR of 24.40% to reach USD 17.98 billion by 2029.
What is the current Advanced Therapy Medicinal Products CDMO Market size?
In 2024, the Advanced Therapy Medicinal Products CDMO Market size is expected to reach USD 6.04 billion.
